XML 30 R18.htm IDEA: XBRL DOCUMENT v3.26.3
SUBSEQUENT EVENTS
9 Months Ended
Sep. 30, 2026
SUBSEQUENT EVENTS  
SUBSEQUENT EVENTS

11. SUBSEQUENT EVENTS

 

On October 29 2026, BioAdaptives. Inc executed a purchase agreement with Xycota Biosciences, LLC, a preclinical biotechnology company, which goal is an oral psilocybin treatment that patients could take at home without hallucinogenic effects. At closing, Xycota would become a wholly owned subsidiary of BioAdaptives and continue under its existing executive and scientific leadership. This acquisition gives stockholders a defined path into CNS biotechnology, with Xycota operating separately, funding tied to closing and milestones. The agreement also provided a possible nutraceutical spin-off. For further details of this transaction, refer to 8K filed on November 4, 2026.